• Alzheimer's trial on track for November results
• 88% enrollment in open-label extension phase
• Positive feedback from EMA and FDA
• Anti-depressant activity publication in British Journal of Psychiatry
• New patents received for Xanamem

Actinogen Medical Ltd. released its June 2026 quarterly activity report, detailing significant progress in their pivotal Alzheimer's disease trial, XanaMIA. The trial remains on track for topline final results in November, with strong ongoing enrollment in the open-label extension phase. The company received positive scientific advice from the European Medicines Agency and the US FDA, aligning with prior feedback. A peer-reviewed manuscript detailing positive anti-depressant activity of Xanamem was published in the British Journal of Psychiatry. Additionally, the company received national acceptances for new patents covering Xanamem treatment of cognitive decline in healthy elderly persons and key manufacturing steps. The company ended the quarter with a cash balance of $16.7 million, providing a cash runway beyond the XanaMIA trial final results to mid-2027.